Status:
ACTIVE_NOT_RECRUITING
Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI
Lead Sponsor:
Medical College of Wisconsin
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this prospective, nonrandomized controlled phase IV study is to compare standard and advanced MRI for their ability to predict response to Optune therapy.
Detailed Description
Protocol Summary: Optune therapy is a newly approved treatment for patients with glioblastoma. This therapy demonstrated comparable outcomes for patients with recurrent GBM, in comparison to standard ...
Eligibility Criteria
Inclusion
- Newly diagnosed glioblastoma (GBM), World Health Organization (WHO) grade IV.
Exclusion
- Optune compliance \< 75%; they would be excluded from the final analyses.
- History of craniectomy or significant skull defect (contraindication to Optune).
- Active implantable medical device (e.g., deep brain stimulator (DBS), spinal cord stimulator, pacemaker, defibrillator, vagus nerve stimulator, programmable shunt).
- Karnofsky Performance Status (KPS) \< 60.
Key Trial Info
Start Date :
December 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03297125
Start Date
December 1 2017
End Date
January 1 2026
Last Update
October 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Froedtert Hospital & Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53202